The biggest ever study of DNA from people with glioma - the most common form of brain cancer - has discovered five new genetic variants associated with the disease.
One variant increases the risk of developing glioblastoma, a particularly aggressive kind of glioma with an average survival of only 10-15 months after diagnosis, by almost a quarter.
Researchers said their findings provided important new evidence for an inherited susceptibility to glioma, and offered potential clues for how to treat or prevent the disease.
Scientists at The Institute of Cancer Research, London, led an international team in analysing DNA from more than 5,637 people who had developed glioma, and comparing it with 9,158 people without the disease.
Their study, published today (Thursday) in Nature Communications, was mainly funded by Cancer Research UK, the Wellcome Trust and the DJ Fielding Medical Research Trust.
The research added analysis of new cases to a 'meta-analysis' of four other previous studies, and pulled together data from people with glioma from Europe, the US and Canada.
Each variant is a one-letter difference in the DNA code which increases the risk of glioma in those who have it. This study brings the total number of genetic variants linked to glioma to 12.
One variant was associated with a 23% increased risk of glioblastoma - although because glioma is a rare disease, the underlying risk to any individual remains small. This variant was close in the DNA code to the gene encoding RNA polymerase III, which plays a complex role in the synthesis and manufacture of intra-cellular messenger molecules that build other proteins.
The other four genetic variants were found to increase the risk of less aggressive, non-glioblastoma forms of glioma by around five per cent each.
These may also act through their effect on other nearby genes. One variant has an intriguing link with a gene called VTI1A, which is involved in nerve development and the cellular response to insulin.
Study leader Professor Richard Houlston, Professor of Molecular and Population Genetics at The Institute of Cancer Research, London, said:
"We believe our study is the largest ever conducted of the genetics of glioma - the most common form of brain cancer - and it provides firm evidence that susceptibility to the disease is in part inherited.
"One of the risk factors we identified is linked to quite a dramatically increased chance of developing glioblastoma, a particularly aggressive kind of brain cancer. Our study sheds fresh light on the biology of gliomas, and could provide clues to why the disease develops, and how it could be treated or prevented."
Dr Aine McCarthy, science information officer at Cancer Research UK, said:
"These are exciting results because identifying genetic mistakes that increase the risk of glioma could be a vital first step towards developing new treatments against the disease. Building on these findings and determining the exact role these genetic changes play in the development of glioma could help doctors personalise treatment for the disease in the future and save more lives."
Notes to editors
For more information please contact Henry French on 020 7153 5282 / email@example.com. For enquiries out of hours, please call 07595 963613.
The Institute of Cancer Research, London, is one of the world's most influential cancer research institutes.
Scientists and clinicians at The Institute of Cancer Research (ICR) are working every day to make a real impact on cancer patients' lives. Through its unique partnership with The Royal Marsden NHS Foundation Trust and 'bench-to-bedside' approach, the ICR is able to create and deliver results in a way that other institutions cannot. Together the two organisations are rated in the top four cancer centres globally.
The ICR has an outstanding record of achievement dating back more than 100 years. It provided the first convincing evidence that DNA damage is the basic cause of cancer, laying the foundation for the now universally accepted idea that cancer is a genetic disease. Today it leads the world at isolating cancer-related genes and discovering new targeted drugs for personalised cancer treatment.
As a college of the University of London, the ICR provides postgraduate higher education of international distinction. It has charitable status and relies on support from partner organisations, charities and the general public.
The ICR's mission is to make the discoveries that defeat cancer. For more information visit http://www.
About Cancer Research UK
- Cancer Research UK is the world's leading cancer charity dedicated to saving lives through research.
- Cancer Research UK's pioneering work into the prevention, diagnosis and treatment of cancer has helped save millions of lives.
- Cancer Research UK receives no government funding for its life-saving research. Every step it makes towards beating cancer relies on every pound donated.
- Cancer Research UK has been at the heart of the progress that has already seen survival in the UK double in the last forty years.
- Today, 2 in 4 people survive their cancer for at least 10 years. Cancer Research UK's ambition is to accelerate progress so that 3 in 4 people will survive their cancer for at least 10 years within the next 20 years.
- Cancer Research UK supports research into all aspects of cancer through the work of over 4,000 scientists, doctors and nurses.
- Together with its partners and supporters, Cancer Research UK's vision is to bring forward the day when all cancers are cured.
For further information about Cancer Research UK's work or to find out how to support the charity, please call 0300 123 1022 or visit http://www.